Subtopic Deep Dive
Androgen Receptor Signaling in Prostate Cancer
Research Guide
What is Androgen Receptor Signaling in Prostate Cancer?
Androgen receptor (AR) signaling drives prostate cancer progression and is targeted by inhibitors like enzalutamide and abiraterone in castration-resistant disease.
AR signaling persists in 90% of advanced prostate cancers despite androgen deprivation, enabling tumor growth via intratumoral androgen synthesis (Montgomery et al., 2008; 1402 citations). Enzalutamide extends survival in post-chemotherapy metastatic cases (Scher et al., 2012; 4508 citations). Resistance arises from AR mutations, variants, and neuroendocrine transdifferentiation (Grasso et al., 2012; 2557 citations; Watson et al., 2015; 1483 citations). Over 10 key papers from 2008-2020 detail these mechanisms.
Why It Matters
AR-targeted therapies like enzalutamide and abiraterone extend survival by 4-5 months in castration-resistant prostate cancer, which comprises 90% of advanced cases (Scher et al., 2012; Attard et al., 2008). Abiraterone inhibits CYP17 to block intratumoral androgen production, confirming hormone-driven CRPC (Attard et al., 2008; 892 citations). Darolutamide delays metastasis in nonmetastatic CRPC (Fizazi et al., 2019; 882 citations). These treatments guide NCCN and ESMO guidelines for managing recurrent and advanced disease (Mohler et al., 2019; Parker et al., 2020). Resistance mechanisms identified in genomic studies inform next-generation inhibitor development (Grasso et al., 2012; Beltran et al., 2016).
Key Research Challenges
AR Inhibitor Resistance
Tumors evade enzalutamide and abiraterone through AR mutations, splice variants, and ligand-independent activation (Watson et al., 2015; 1483 citations). Intratumoral androgen synthesis persists despite castration (Montgomery et al., 2008; 1402 citations). Over 1483-cited reviews detail these adaptive pathways.
Neuroendocrine Transdifferentiation
Castration-resistant neuroendocrine prostate cancer (CRPC-NE) emerges via clonal evolution, bypassing AR signaling (Beltran et al., 2016; 1666 citations). Lineage plasticity drives aggressive, treatment-refractory disease. Genomic profiling reveals divergent mutations from adenocarcinoma.
Intratumoral Androgen Synthesis
CRPC maintains androgen levels through upregulated steroidogenesis enzymes despite systemic suppression (Montgomery et al., 2008; 1402 citations). CYP17 inhibition with abiraterone partially counters this but resistance develops (Attard et al., 2008; 892 citations). Quantifying de novo synthesis remains critical.
Essential Papers
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher, Karim Fizazi, Fred Saad et al. · 2012 · New England Journal of Medicine · 4.5K citations
Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer after chemotherapy. (Funded by Medivation and Astellas Pharma Global Development; AFFIR...
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso, Yi-Mi Wu, Dan R. Robinson et al. · 2012 · Nature · 2.6K citations
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Himisha Beltran, Davide Prandi, Juan Miguel Mosquera et al. · 2016 · Nature Medicine · 1.7K citations
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
James L. Mohler, Emmanuel S. Antonarakis, Andrew J. Armstrong et al. · 2019 · Journal of the National Comprehensive Cancer Network · 1.5K citations
The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advance...
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Philip A. Watson, Vivek Arora, Charles L. Sawyers · 2015 · Nature reviews. Cancer · 1.5K citations
Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
Bruce Montgomery, Elahe A. Mostaghel, Robert L. Vessella et al. · 2008 · Cancer Research · 1.4K citations
Abstract Therapy for advanced prostate cancer centers on suppressing systemic androgens and blocking activation of the androgen receptor (AR). Despite anorchid serum androgen levels, nearly all pat...
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Chris Parker, Elena Castro, Karim Fizazi et al. · 2020 · Annals of Oncology · 892 citations
Reading Guide
Foundational Papers
Start with Scher et al. (2012; 4508 citations) for enzalutamide survival benchmark, Montgomery et al. (2008; 1402 citations) for intratumoral androgen mechanism, and Grasso et al. (2012; 2557 citations) for mutational drivers establishing CRPC biology.
Recent Advances
Study Beltran et al. (2016; 1666 citations) on neuroendocrine evolution, Fizazi et al. (2019; 882 citations) on darolutamide, and Watson et al. (2015; 1483 citations) on resistance mechanisms.
Core Methods
AR structure-function analysis (Tan et al., 2014); CYP17 inhibition trials (Attard et al., 2008); genomic sequencing for mutations (Grasso et al., 2012); clonal evolution tracking (Beltran et al., 2016).
How PapersFlow Helps You Research Androgen Receptor Signaling in Prostate Cancer
Discover & Search
Research Agent uses searchPapers('androgen receptor variants prostate cancer resistance') to find Scher et al. (2012; 4508 citations), then citationGraph reveals downstream works like Watson et al. (2015), and findSimilarPapers expands to Grasso et al. (2012). exaSearch queries 'AR signaling castration-resistant mechanisms' for 250M+ OpenAlex papers.
Analyze & Verify
Analysis Agent applies readPaperContent on Montgomery et al. (2008) to extract intratumoral androgen data, verifyResponse with CoVe checks claims against 10 provided papers, and runPythonAnalysis plots survival curves from Scher et al. (2012) AFFIRM trial data using pandas/matplotlib. GRADE grading scores enzalutamide evidence as high-quality (Scher et al., 2012).
Synthesize & Write
Synthesis Agent detects gaps in AR variant coverage across Grasso (2012) and Beltran (2016), flags contradictions in resistance models, and uses exportMermaid for AR signaling pathway diagrams. Writing Agent employs latexEditText for review drafting, latexSyncCitations integrates 10 papers, and latexCompile generates polished manuscripts.
Use Cases
"Extract and plot Kaplan-Meier survival data from enzalutamide AFFIRM trial"
Research Agent → searchPapers('Scher enzalutamide AFFIRM') → Analysis Agent → readPaperContent → runPythonAnalysis(pandas survival plot) → matplotlib figure of 4.8-month OS gain.
"Draft LaTeX review section on AR inhibitor resistance mechanisms"
Synthesis Agent → gap detection (Watson 2015 + Grasso 2012) → Writing Agent → latexEditText('resistance section') → latexSyncCitations(10 papers) → latexCompile → export PDF with AR pathway figure.
"Find GitHub repos analyzing AR mutation data from Grasso 2012"
Research Agent → searchPapers('Grasso mutational landscape') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → R scripts for variant frequency analysis.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ AR signaling papers) → citationGraph → DeepScan(7-step: readPaperContent → verifyResponse → GRADE) → structured report on resistance. Theorizer generates hypotheses on neuroendocrine bypass from Beltran (2016) + Montgomery (2008). Chain-of-Verification/CoVe verifies all claims against Scher (2012) benchmark.
Frequently Asked Questions
What defines androgen receptor signaling in prostate cancer?
AR binds androgens to activate transcription driving proliferation; persists in CRPC via intratumoral synthesis (Montgomery et al., 2008) and mutations (Grasso et al., 2012).
What are key methods targeting AR signaling?
Enzalutamide blocks AR nuclear translocation (Scher et al., 2012); abiraterone inhibits CYP17 for androgen depletion (Attard et al., 2008); darolutamide used in nonmetastatic CRPC (Fizazi et al., 2019).
What are seminal papers on AR signaling?
Scher et al. (2012; 4508 citations) on enzalutamide survival; Grasso et al. (2012; 2557 citations) on CRPC mutations; Montgomery et al. (2008; 1402 citations) on intratumoral androgens.
What open problems exist in AR signaling research?
Overcoming resistance via AR variants (Watson et al., 2015); neuroendocrine transdifferentiation (Beltran et al., 2016); sustained intratumoral androgen production despite CYP17 inhibition.
Research Prostate Cancer Treatment and Research with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Androgen Receptor Signaling in Prostate Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.